Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Cyclo Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo
Cyclo Announces Allowance of Patent Application for Alzheimer’s Disease
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Cyclo Announces Outcome from Meeting with FDA Discussing Trappsol Cyclo Program
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement